Efficacy of artificial liver support system in treatment of acute-on-chronic liver failure: A network Meta-analysis
10.3969/j.issn.1001-5256.2022.01.021
- VernacularTitle:人工肝支持系统治疗慢加急性肝衰竭效果的网状Meta分析
- Author:
Liangliang GAN
1
;
Jinzhou ZHANG
1
;
Xiandong WANG
1
;
Caihong FU
1
;
Jia SU
1
;
Xuemei TANG
1
Author Information
1. Department of Critical Care Medicine, Gansu Provincial Hospital, Lanzhou 730000, China
- Publication Type:Original Articles_Other Liver Diseases
- Keywords:
Acute-On-Chronic Liver Failure;
Liver, Artificial;
Meta-Analysis as Topic
- From:
Journal of Clinical Hepatology
2022;38(1):135-140
- CountryChina
- Language:Chinese
-
Abstract:
Objective To systematically review the efficacy of different artificial liver support systems in the treatment of acute-on-chronic liver failure (ACLF) using a network Meta-analysis. Methods PubMed, Embase, the Cochrane library, Clinical Trial, CNKI, SinoMed, and Wanfang Data were searched for randomized controlled trials (RCTs) on different artificial liver support systems in the treatment of ACLF. Literature screening, data extraction, and method ological quality assessment were performed according to inclusion and exclusion criteria, and Stata15.1 software and R4.1.0 software were used to perform a network Meta-analysis. Results A total of 14 RCTs were included, with 1141 patients in total. The network meta-analysis showed different intervention methods had no significant difference in reducing mortality rate based on cross comparison (all P > 0.05). The probability ranking diagram showed that plasma exchange (PE) showed the best effect in reducing 30-day mortality rate, followed by extracorporeal liver assist device (ELAD), fractionated plasma separation and adsorption with Prometheus system, molecular adsorbent recirculating system (MARS), Biologic-DT liver dialysis device, and PE+MARS. PE showed the best effect in reducing 90-day mortality rate, followed by Prometheus, ELAD, and MARS. Biologic-DT showed the best effect in improving hepatic encephalopathy, followed by MARS, PE+MARS, and ELAD. Patients undergoing ELAD had the lowest risk of bleeding, and compared with standard medical treatment, Biologic-DT might increase the risk of bleeding [risk ratio=1.9×10 8 , 95% confidence interval: (4.6-6.2)×10 27 ]. Conclusion PE might be the best option for reducing 30- and 90-day mortality rates in ACLF patients. Biologic-DT has a better effect in improving hepatic encephalopathy, but it may increase the risk of bleeding.
